GlassScriptPhysician profile
Raymond E Winicki
NPI 1720083421
$6,414.37
in general payments reported to CMS, 2019-2025
25 companies · $1,038 in 2025
The $1,038 reported for 2025 was more than what 80% of Otolaryngology providers received nationally (typical 2025 total: $317).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,742 · 2020: $1,046 · 2021: $179 · 2022: $279 · 2023: $566 · 2024: $564 · 2025: $1,038.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,134 · Education: $34.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,134.26 |
| Education | $34.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intersect Ent, INC. | $2,942.26 | 2019-2022 | |
| Medical Device Business Services, INC. | $882.52 | 2020 | |
| Glaxosmithkline, LLC. | $531.12 | 2023-2025 | Nucala |
| Regeneron Healthcare Solutions, INC. | $367.94 | 2022-2025 | Dupixent |
| Optinose US, INC. | $345.12 | 2019-2025 | |
| Genentech USA, INC. | $144.44 | 2019 | |
| Phathom Pharmaceuticals, INC. | $131.35 | 2024-2025 | Voquezna |
| Genzyme Corporation | $128.00 | 2019-2025 | |
| Stryker Corporation | $119.74 | 2022-2025 | Scopis Ent, Xpress Loprofile |
| Takeda Pharmaceuticals U.S.A., INC. | $115.26 | 2023-2025 | Takhzyro, Hyqvia, Elaprase |
| Novartis Pharmaceuticals Corporation | $99.99 | 2023-2024 | |
| Pharming Healthcare, INC. | $94.07 | 2023-2025 | Ruconest |
| Amgen INC. | $90.79 | 2023-2025 | Tezspire |
| Acclarent, INC | $84.81 | 2019-2023 | Trudi Nav Cable |
| Grifols USA, LLC | $76.59 | 2023-2025 | Xembify |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cycle Pharmaceuticals INC | $56.95 | 2024-2025 | Sajazir |
| Aerin Medical INC. | $47.97 | 2025 | |
| Csl Behring | $29.29 | 2025 | Andembry |
| Pfizer INC. | $24.89 | 2023 | |
| Mylan Specialty L.P. | $19.98 | 2023 | Yupelri |
| Teleflex LLC | $19.11 | 2023 | Urolift |
| Neurent Medical Limited | $18.00 | 2024 | Neuromark Device, Neuromark Radiofrequency Console |
| Astrazeneca Pharmaceuticals LP | $15.80 | 2023 | Tezspire |
| Ars Pharmaceuticals Operations, INC. | $15.02 | 2025 | Neffy |
| Hikma Pharmaceuticals USA | $13.36 | 2023 | Ryaltris |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Raymond Winicki listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.